Expression of Serum miR-16, let-7f, and miR-21 in Patients with Hepatocellular Carcinoma and their Clinical Significances

Ge, Wei; Yu, Decai; Li, Qingguo; Chen, Xi; Zhang, Chenyu; Ding, Yi-Tao

doi:10.7754/clin.lab.2013.130133

Cited by 59 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This role was further confirmed by Tsang and Kwok (2010), who showed that the introduction of epigallocathechinagallate (EGCG) increases tissue levels of miR-16 favoring the suppression of Bcl-2. Similarly, it has been reported that serum levels of miR-16 are significantly lower in HCC than in chronic liver disease (CLD) patients or control subjects (Ge et al, 2014). In addition, these authors confirmed how this test may be used in association with other markers reaching a good diagnostic performance with high sensitivity and specificity, in particular, if the analysis is restricted to tumors more than 3 cm as diameter .…”

Section: Mir-16supporting

confidence: 55%

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

Bronte

Fanale

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Section: Mir-16supporting

confidence: 55%

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

Bronte

Fanale

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…The miR-885-5p and miR-122-5p in serum was reported related to cholesterol reverse transport and assessment of liver pathologies111. In addition, miR-101-3p, miR-106b-5p, miR-130a-3p, miR-16-5p, miR-199a-5p, let-7f-5p and miR-34a-5p were found to have a significant correlation with tumor size in the tissue and serum of HCC patients5064102112113114. The present literature also provided evidence that miR-130a-3p, miR-21-5p, miR-25-3p, miR-17-5p were independent prognostic factors and were associated with the TNM classification which is a universally accepted cancer staging system based on extension and size of the primary tumor (T), the adjacent lymph node (N), and the distant metastasis (M)686978102.…”

Section: Resultsmentioning

confidence: 99%

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

Shen

Lin

Yuan

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Hepatocellular Carcinoma (HCC) is one of the most common malignant tumors with high incidence and mortality rate. Precision and effective biomarkers are therefore urgently needed for the early diagnosis and prognostic estimation. MicroRNAs (miRNAs) are important regulators which play functions in various cellular processes and biological activities. Accumulating evidence indicated that the abnormal expression of miRNAs are closely associated with HCC initiation and progression. Recently, many biomarker miRNAs for HCC have been identified from blood or tissues samples, however, the universality and specificity on clinicopathological features of them are less investigated. In this review, we comprehensively surveyed and compared the diagnostic, prognostic, and therapeutic roles of HCC biomarker miRNAs in blood and tissues based on the cancer hallmarks, etiological factors as well as ethnic groups, which will be helpful to the understanding of the pathogenesis of biomarker miRNAs in HCC development and further provide accurate clinical decisions for HCC diagnosis and treatment.

show abstract

“…Accordingly, higher incidence of HCC was observed in males as reported by other studies. [24][25][26][27] Results showed no statistically significant differences between the subjects of the three groups concerning age, sex, and smoking status. This was in accordance with previous studies.…”

Section: Discussionmentioning

confidence: 99%

Role of microRNA-7 and selenoprotein P in hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). IntroductionHepatocellular carcinoma (HCC) represents the fifth most common cancer and the third most leading cause of cancer-related deaths worldwide. 1 High morbidity observed in HCC is majorly attributed to the lack of early detection markers and poor prognosis. Hence, exploration of novel frontiers in HCC diagnosis and therapeutics remains to be high priority research areas. 2,3 HCC represents a public health problem in Egypt. It constitutes 70.48% of all liver tumors among Egyptians, representing the second most common malignancy after bladder cancer in men and breast cancer in women and the second most common cause of death in men. 4,5 Alpha-fetoprotein (AFP) is the most widely used tumor biomarker for HCC diagnosis. However, it has low sensitivity and specificity. This highlights the need for other methods that would be minimally invasive, simple, and reliable. 6 MicroRNAs (miRNAs) are a class of short non-coding RNAs, which play a central role in sequence specific posttranscriptional gene attenuation. 7 They are involved in various fundamental cellular processes as well as carcinogenesis. Moreover, miRNAs are highly stable in serum due to their resistance to RNase, extreme pH, and temperature. Therefore, they have been identified as candidate AbstractThere is an obvious need to diagnose hepatocellular carcinoma using novel non-invasive and sensitive biomarkers. In this regard, the aim of this study was to evaluate and correlate both relative quantification of microRNA-7 using quantitative real time polymerase chain reaction and quantitative analysis of selenoprotein P using enzyme-linked immunosorbent assay in sera of hepatocellular carcinoma patients, chronic liver disease patients, as well as normal healthy subjects in order to establish a new diagnostic biomarker with a valid non-invasive technique. In addition, this study aimed to investigate whether changes in selenium supply affect microRNA-7 expression and selenoprotein P levels in human hepatocarcinoma cell line (HepG2). The results showed a highly significant decrease in serum microRNA-7 relative quantification values and selenoprotein P levels in malignant group in comparison with benign and control groups. The best cutoff for serum microRNA-7 and selenoprotein P to discriminate hepatocellular carcinoma group from benign and control groups was 0.06 and 4.30 mg/L, respectively. Furthermore, this study showed that changes in selenium supply to HepG2 cell line can alter the microRNA-7 profile and are paralleled by changes in the concentration of its target protein (selenoprotein P). Hence, serum microRNA-7 ...

show abstract

Expression of Serum miR-16, let-7f, and miR-21 in Patients with Hepatocellular Carcinoma and their Clinical Significances

Cited by 59 publications

References 0 publications

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

Role of microRNA-7 and selenoprotein P in hepatocellular carcinoma

Contact Info

Product

Resources

About